The thyroid papillary and follicular carcinoma with the most commonly tissue category, important depended on surgical ablation, internal radiation with 131 I and endocrine therapy of thyroxine, belongs to differentiated cancers. The 131 I based on special ability of uptaking and utilizing I is a most and efficient radiopharmaceuticals with specificity at presence in view of Na + /I-symporter (NIS) in thyrocytes, in brief, the key to treatment with 131 I is absorbing capability of thyroid cancer. The one in third of differentiated thyroid carcinoma, however, lost ability of uptaking iodine because of dedifferentiated cell so that treatment with 131 I result in poor prognosis, those importantly manifest low-expression of NIS, un-expression or located expression on cytoplasm in thyroid carcinoma tissue [1] . How to improve the absorbing iodine of dedifferentiated thyroid carcinoma is a hotspot at presence [2, 3] . The research explored clinical therapeutic effect and induced expression of NIS and iodine uptake using radiofrequency connected with 131 I in 29 cases of dedifferentiated thyroid cancer.
Materials and methodsWe selected low expression and un-expression of NIS of 29 recurrent and metastatic cases with thyroid carcinoma after surgery and treatment of 131 I in our institution from June 2005 to May 2009, and assay expression of NIS using immunohistochemistry .
Clinical dataThere were 11 males and 18 females, the middle age was 43.8 years (age ranged from 14 to 69 years), including 20 cases of thyroid papillary carcinoma and 9 cases of follicular carcinoma; 17 cases of neck recurrence and metastasis and 7 cases of bone metastasis and 5 cases of pulmonary metastasis. There were at least one therapy using 131 iodine with 5.55-47.8 GBq (mean 21.5 GBq). All patients with Karnofsky score ≥ 70 and normal routine blood assay and heart function, pulmonary, hepatic function were not accepted any chemical, irradiated, 131 I therapy within three month.
ImmunohistochemistryImmunostaining was performed in all cases after pathological final diagnosis. The NIS which were Millipore company (USA) was detected by SP immunohistochemistry using NIS monoclonal antibody in 432 negative cervical lymph nodes of 83 cases detected routine pathological examination to confirm lymph node micrometastases. SP reagent kit were provided by BOSHIDE Company of Wuhan (China). Positive and negative controls were obtained using positive sample and obtained NIS.Immunohistochemical staining was independently evaluated by two pathologists unaware of sample origin, positive expression of NIS were located in the cell memAbstract Objective: The aim of this study was to explore clinical efficiency of radio frequency combined with 131 I therapy for dedifferentiated thyroid carcinoma. Methods: All patients have been treated by radiofrequency connected with 131 I in 29 cases of dedifferentiated thyroid carcinoma which performed radionuclide imaging and Ig array of blood serum before and after therapy, respectively. Results: There were 4 (4/29) positive ca...